AssetMemo
AssetsMechanismsCompaniesCalendarChartsWatchlistAsk AIMethodology
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
◧AssetMemo
⌕

Evidence-graded drug-asset intelligence
◧AssetMemo
AssetsMechanismsCompaniesReadout CalendarCompare ChartsWatchlist & AlertsAsk AI
Therapeutic areas
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
ReferenceMethodology & RubricUs vs. AI ToolsUK IBD Access GuideAbout the founder

Educational data tool. Evidence graded; securities never are.

BrowseAll assetsAll mechanismsAll companiesReadout calendarReadouts by yearResults by diseaseDelayed readoutsOpen dataCompare share pricesWhat's new
ReferenceMethodology & sourcesUs vs. the AI toolsUK IBD Access GuideAbout the founderAsk the AIReport a problem / suggest a feature

Educational research only, not investment advice. Evidence quality is graded; securities never are. · Terms · Privacy · Logos by Logo.dev

Ask

Opening the console…

1,457 drug developers and their pipelines

Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.

Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.

← browse by therapeutic area

Views

1457 of 1457 companies

CompanyPipelineMost advancedNext readoutMarket capCash & inv.RunwayR&D / yr
M
Maruishi Pharmaceutical Co., Ltd.Private
1 asset: 1 approvedApproved assets only15 Aug 2029Difelikefalin · Phase 2————
MC2 Therapeutics logo
MC2 TherapeuticsPrivate
2 assets: 1 approved, 1 Ph 2MC2-25Phase 2 · Chronic Kidney DiseasePartial signalNone on record————
Medice logo
MedicePrivate
1 asset: 1 approvedApproved assets onlyNone on record————
Mediforum Ltd., Co. logo
Mediforum Ltd., Co.Private
1 asset: 1 Ph 3PM012Phase 2/3 · Alzheimer's DiseasePartial signalNone on record————
MediLink Therapeutics (Suzhou) Co., Ltd. logo
MediLink Therapeutics (Suzhou) Co., Ltd.Private
2 assets: 2 Ph 3Beruzatatug pelitecanPhase 3 · Non-Small Cell Lung CancerNov 2026Beruzatatug pelitecan · Phase 2————
MedImmune LLC logo
MedImmune LLCPrivate
5 assets: 3 approved, 2 Ph 3MonalizumabPhase 3 · Non-Small Cell Lung CancerPartial signal30 Nov 2026Tremelimumab · Phase 2————
M
Medison PharmaPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
M
MedixPrivate
1 asset: 1 Ph 3TesofensinePhase 3 · ObesityReliable signalNone on record————
M
Medunik USAPrivate
1 asset: 1 approvedApproved assets onlyFeb 2028Hydroxyurea (Siklos) · Phase 2————
Meiji Seika Pharma logo
Meiji Seika PharmaPrivate
4 assets: 2 approved, 1 Ph 3, 1 Ph 2ChidamidePhase 3 · HR+/HER2- Metastatic Breast CancerReliable signal26 Jan 2027Belumosudil · Phase 1————
Meitheal Pharmaceuticals logo
Meitheal PharmaceuticalsPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
Memgen, Inc. logo
Memgen, Inc.Private
1 asset: 1 Ph 1MEM-288Phase 1 · Non-Small Cell Lung CancerFeb 2027MEM-288 · Phase 1————
Meridigen Biotech logo
Meridigen BiotechPrivate
1 asset: 1 Ph 2SolizmestrocelPhase 2 · Chronic Obstructive Pulmonary DiseaseWeak signalNone on record————
Merry Life Biomedical Co., Ltd. logo
Merry Life Biomedical Co., Ltd.Private
1 asset: 1 Ph 2TML-6Phase 2 · Alzheimer's DiseaseWeak signal30 Apr 2028TML-6 · Phase 2————
Merus N.V. logo
Merus N.V.Private
2 assets: 1 approved, 1 Ph 2PamvatamigPhase 2 · Non-Small Cell Lung Cancer31 Dec 2026Zenocutuzumab · Phase 2—$367MSep 2025Ended Sep 2026$328M
M
MeryxPrivate
1 asset: 1 Ph 2MRX-2843Phase 1/2 · Acute Myeloid LeukemiaWeak signalNone on record————
Merz Pharmaceuticals logo
Merz PharmaceuticalsPrivate
1 asset: 1 Ph 3IncobotulinumtoxinA (Xeomin)Phase 3 · Parkinson's DiseaseNone on record————
Merz Therapeutics logo
Merz TherapeuticsPrivate
2 assets: 2 approvedApproved assets onlyNone on record————
Microbiotica logo
MicrobioticaPrivate
1 asset: 1 Ph 1MB310Phase 1 · Ulcerative ColitisPartial signalNone on record————
M
Midas Pharma GmbHPrivate
1 asset: 1 otherRanibizumab (Ranivisio)Age-Related Macular DegenerationNone on record————
MindRank AI logo
MindRank AIPrivate
1 asset: 1 Ph 3MDR-001Phase 3 · ObesityJun 2027MDR-001 · Phase 3————
M
MingSight Pharmaceuticals, Inc.Private
1 asset: 1 Ph 2MS-553Phase 1/2 · Chronic Lymphocytic LeukemiaSep 2028MS-553 · Phase 1/2————
Mirador Therapeutics logo
Mirador TherapeuticsPrivate
2 assets: 2 Ph 2MT-201Phase 2 · Ulcerative Colitis30 Apr 2027MT-501 · Phase 2————
Mission Therapeutics logo
Mission TherapeuticsPrivate
1 asset: 1 Ph 1MTX325Phase 1 · Parkinson's Disease30 Jun 2027MTX325 · Phase 1————
MODAG GmbH logo
MODAG GmbHPrivate
1 asset: 1 Ph 1EmrusolminPhase 1 · Parkinson's DiseasePartial signal15 Jan 2027Emrusolmin · Phase 1————
Moleac Pte Ltd logo
Moleac Pte LtdPrivate
1 asset: 1 Ph 3MLC901Phase 3 · Alzheimer's DiseaseFeb 2029MLC901 · Phase 3————
Mthera Pharma Co., Ltd. logo
Mthera Pharma Co., Ltd.Private
1 asset: 1 Ph 2MT101-5Phase 2 · Parkinson's DiseasePartial signalJan 2028MT101-5 · Phase 2————
MTI Biotech Inc. logo
MTI Biotech Inc.Private
1 asset: 1 Ph 22-hydroxybenzylamine acetatePhase 1/2 · Alzheimer's Disease30 Dec 20282-hydroxybenzylamine acetate · Phase 1/2————
Multitude Therapeutics Inc. logo
Multitude Therapeutics Inc.Private
1 asset: 1 Ph 3AMT-116Phase 2/3 · Non-Small Cell Lung Cancer30 Dec 2026AMT-116 · Phase 1————
Nammi Therapeutics Inc logo
Nammi Therapeutics IncPrivate
1 asset: 1 Ph 1QXL138AMPhase 1 · Multiple Myeloma31 Dec 2027QXL138AM · Phase 1————
Nanjing Immunophage Biotech logo
Nanjing Immunophage BiotechPrivate
1 asset: 1 Ph 2IPG11406Phase 2 · Ulcerative ColitisWeak signal20 Nov 2028IPG11406 · Phase 2————
Nanjing RegeneCore Biotech logo
Nanjing RegeneCore BiotechPrivate
1 asset: 1 Ph 2RC1416Phase 2 · Chronic Obstructive Pulmonary Disease25 Oct 2027RC1416 · Phase 2————
Nanjing Sanhome Pharmaceutical logo
Nanjing Sanhome PharmaceuticalPrivate
2 assets: 1 Ph 3, 1 Ph 1Rilertinib (SH-1028)Phase 3 · Non-Small Cell Lung CancerReliable signal30 Dec 2026SH009 · Phase 1————
Nanogen Pharmaceutical Biotechnology logo
Nanogen Pharmaceutical BiotechnologyPrivate
1 asset: 1 Ph 3NNG-DEPOPhase 3 · Chronic Kidney DiseasePartial signalNone on record————
Napo Pharmaceuticals logo
Napo PharmaceuticalsPrivate
1 asset: 1 approvedApproved assets onlyDec 2026Crofelemer · Phase 2/3————
Navigen logo
NavigenPrivate
1 asset: 1 Ph 1CPT31Phase 1 · HIVWeak signalNone on record————
nChroma Bio, Inc. logo
nChroma Bio, Inc.Private
1 asset: 1 Ph 2CRMA-1001Phase 1/2 · Chronic Hepatitis BFeb 2031CRMA-1001 · Phase 1/2————
N
ND Partners, LLCPrivate
1 asset: 1 approvedApproved assets onlyJan 2028Taurolidine/heparin · Phase 3————
N
NeoImmuneTechPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
NeoTX Therapeutics Ltd. logo
NeoTX Therapeutics Ltd.Private
1 asset: 1 Ph 2Naptumomab estafenatoxPhase 2 · Non-Small Cell Lung CancerWeak signal1 Mar 2027Naptumomab estafenatox · Phase 1————
Nerviano Medical Sciences logo
Nerviano Medical SciencesPrivate
1 asset: 1 Ph 1NMS-03597812Phase 1 · Acute Myeloid LeukemiaNone on record————
Nerviano Medical Sciences (Shanghai) Ltd. logo
Nerviano Medical Sciences (Shanghai) Ltd.Private
1 asset: 1 Ph 2atamparibPhase 1/2 · Non-Small Cell Lung Cancer31 Jul 2028atamparib · Phase 1/2————
Nested Therapeutics, Inc logo
Nested Therapeutics, IncPrivate
1 asset: 1 Ph 1NST-628Phase 1 · Non-Small Cell Lung CancerNov 2028NST-628 · Phase 1————
N
Nestle Health SciencePrivate
1 asset: 1 approvedApproved assets onlyNone on record————
N
NeuraxpharmPrivate
1 asset: 1 approvedApproved assets only21 Jan 2027Ublituximab · Phase 3————
Neurelis, Inc. logo
Neurelis, Inc.Private
1 asset: 1 approvedApproved assets onlyNone on record————
Neurim Pharmaceuticals Ltd. logo
Neurim Pharmaceuticals Ltd.Private
1 asset: 1 Ph 3Melatonin prolonged-releasePhase 3None on record————
NeuroActiva Inc. (subsidiary of Biomed Industries Inc.) logo
NeuroActiva Inc. (subsidiary of Biomed Industries Inc.)Private
1 asset: 1 Ph 2TraneurocinPhase 2 · Alzheimer's DiseasePartial signalNone on record————
NEUROBiOGEN logo
NEUROBiOGENPrivate
1 asset: 1 Ph 2TisolagilinePhase 2 · Obesity31 Jan 2027Tisolagiline · Phase 2————
NeuroDerm Ltd. logo
NeuroDerm Ltd.Private
1 asset: 1 Ph 3Levodopa/carbidopa (ND0612)Phase 3 · Parkinson's DiseasePartial signalNone on record————
N
NeuroGen PharmaPrivate
2 assets: 2 approvedApproved assets onlyNone on record————
Neurolixis logo
NeurolixisPrivate
1 asset: 1 Ph 2BefiradolPhase 2 · Parkinson's DiseaseWeak signalNone on record————
Neuron23 logo
Neuron23Private
1 asset: 1 Ph 2NEU-411Phase 2 · Parkinson's DiseaseDec 2027NEU-411 · Phase 2————
Neuronascent, Inc. logo
Neuronascent, Inc.Private
1 asset: 1 Ph 1NNI-362Phase 1 · Alzheimer's DiseaseWeak signalNone on record————
NeuroPro Therapeutics, Inc. logo
NeuroPro Therapeutics, Inc.Private
1 asset: 1 Ph 2NPT2042Phase 2 · EpilepsyPartial signalNone on record————
Neurosterix Pharma Sàrl logo
Neurosterix Pharma SàrlPrivate
1 asset: 1 Ph 1NTX-253Phase 1 · SchizophreniaNone on record————
NeuroTherapia, Inc. logo
NeuroTherapia, Inc.Private
1 asset: 1 Ph 2NTRX-07Phase 2 · Alzheimer's DiseaseWeak signalNone on record————
Newave Pharmaceutical Inc logo
Newave Pharmaceutical IncPrivate
1 asset: 1 Ph 1NexatoclaxPhase 1 · Acute Myeloid Leukemia31 Dec 2026Nexatoclax · Phase 1————
N
Newleos TherapeuticsPrivate
1 asset: 1 Ph 2BasmisanilPhase 21 May 2029Basmisanil · Phase 2————
Newsoara Biopharma logo
Newsoara BiopharmaPrivate
3 assets: 1 approved, 1 Ph 3, 1 Ph 1Prifemilast (HPP737)Phase 3 · PsoriasisPartial signal1 Dec 2026HY1272 · Phase 1————
N
Newsoara HYK Biopharmaceuticals Co., Ltd.Private
1 asset: 1 Ph 3Olvimulogene nanivacirepvecPhase 3 · Ovarian CancerDec 2026Olvimulogene nanivacirepvec · Phase 3————
NGM Biopharmaceuticals logo
NGM BiopharmaceuticalsPrivate
1 asset: 1 Ph 2NGM707Phase 1/2 · Non-Small Cell Lung CancerWeak signalNone on record—$61MDec 2023Ended Feb 2024$118M
N
Nicoya TherapeuticsPrivate
1 asset: 1 approvedApproved assets onlyOct 2027Extended-release calcifediol · Phase 2————
NiKang Therapeutics, Inc. logo
NiKang Therapeutics, Inc.Private
1 asset: 1 Ph 1NKT5097Phase 1 · HR+/HER2- Metastatic Breast Cancer31 Jul 2027NKT5097 · Phase 1————
Nimbus Saturn, Inc. logo
Nimbus Saturn, Inc.Private
1 asset: 1 Ph 2NDI-101150Phase 1/2 · Non-Small Cell Lung CancerNone on record————
NImmune Biopharma logo
NImmune BiopharmaPrivate
2 assets: 1 Ph 2, 1 Ph 1omilancorPhase 2 · Ulcerative ColitisPartial signalNone on record————
Ningbo/Zhejiang Wenda Pharma Technology Co. logo
Ningbo/Zhejiang Wenda Pharma Technology Co.Private
1 asset: 1 Ph 3WD-890Phase 3 · Psoriasis30 Nov 2026WD-890 · Phase 3————
Nizhpharm logo
NizhpharmPrivate
1 asset: 1 Ph 3ChidamidePhase 3 · HR+/HER2- Metastatic Breast CancerReliable signal31 May 2028Chidamide · Phase 3————
N
Nordic Group B.V.Private
1 asset: 1 Ph 3S-1Phase 3 · Non-Small Cell Lung CancerNone on record————
Norgine logo
NorginePrivate
1 asset: 1 Ph 3Tobevibart (VIR-3434)Phase 3 · Chronic Hepatitis DeltaDec 2026Tobevibart (VIR-3434) · Phase 3————
Normunity AccelCo, Inc. logo
Normunity AccelCo, Inc.Private
1 asset: 1 Ph 1NRM-823Phase 1 · Non-Small Cell Lung Cancer30 May 2027NRM-823 · Phase 1————
NorthSea Therapeutics B.V. logo
NorthSea Therapeutics B.V.Private
1 asset: 1 Ph 2SEFA-1024Phase 2 · Severe HypertriglyceridemiaPartial signalNone on record————
Nova Laboratories Limited logo
Nova Laboratories LimitedPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
Novaliq logo
NovaliqPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
Novaremed Ltd. (subsidiary of Novaremed AG) logo
Novaremed Ltd. (subsidiary of Novaremed AG)Private
1 asset: 1 Ph 2Nispomeben (NRD135S.E1)Phase 2 · Diabetic Peripheral Neuropathic PainPartial signalNone on record————
Novatim Immune Therapeutics (Zhejiang) Co., Ltd. logo
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.Private
1 asset: 1 Ph 2KQ-2003Phase 1/2 · Multiple MyelomaWeak signal31 Dec 2027KQ-2003 · Phase 1————
NSC-Therapeutics logo
NSC-TherapeuticsPrivate
1 asset: 1 Ph 2NSC001Phase 1/2 · Alzheimer's DiseaseNone on record————
Nuance Pharma logo
Nuance PharmaPrivate
1 asset: 1 approvedApproved assets only1 Mar 2027ensifentrine · Phase 2————
Nuravax, Inc. logo
Nuravax, Inc.Private
2 assets: 1 Ph 2, 1 Ph 1AV-1959RPhase 2 · Alzheimer's DiseaseWeak signal1 Apr 2027DUVAX · Phase 1————
NurrOn Pharmaceuticals logo
NurrOn PharmaceuticalsPrivate
1 asset: 1 Ph 1ATH-399A (HL192)Phase 1 · Parkinson's DiseaseNone on record————
Nuvalent, Inc. logo
Nuvalent, Inc.Private
3 assets: 1 approved, 1 Ph 3, 1 Ph 1neladalkibPhase 3 · Non-Small Cell Lung CancerJan 2027NVL-330 · Phase 1—$1.3BMar 2026~16.5 qtrs$316M
Nuwacell Biotechnologies Co., Ltd. logo
Nuwacell Biotechnologies Co., Ltd.Private
2 assets: 1 Ph 2, 1 Ph 1NCR201Phase 2 · Parkinson's DiseaseOct 2028NCR201 · Phase 1————
Odyssey Therapeutics logo
Odyssey TherapeuticsPrivate
1 asset: 1 Ph 2OD-07656Phase 2 · Ulcerative ColitisWeak signalNone on record————
Oils4Cure logo
Oils4CurePrivate
1 asset: 1 Ph 3YCJ-01Phase 3 · EpilepsyNone on record————
Oligomerix, Inc logo
Oligomerix, IncPrivate
1 asset: 1 Ph 1OLX-07010Phase 1 · Alzheimer's DiseaseNone on record————
Onchilles Pharma Inc logo
Onchilles Pharma IncPrivate
1 asset: 1 Ph 2N17350Phase 1/2 · Non-Small Cell Lung CancerJul 2028N17350 · Phase 1/2————
OncoC4, Inc. logo
OncoC4, Inc.Private
2 assets: 1 Ph 3, 1 Ph 1GotistobartPhase 3 · Non-Small Cell Lung Cancer30 Nov 2026Gotistobart · Phase 1/2————
OncoPep, Inc. logo
OncoPep, Inc.Private
1 asset: 1 Ph 1PVX-410Phase 1 · Multiple MyelomaWeak signalNone on record————
OncoResponse, Inc. logo
OncoResponse, Inc.Private
1 asset: 1 Ph 2OR502Phase 1/2 · Non-Small Cell Lung CancerNone on record————
OncoVerity, Inc. logo
OncoVerity, Inc.Private
1 asset: 1 Ph 2CusatuzumabPhase 2 · Acute Myeloid LeukemiaWeak signalJan 2027Cusatuzumab · Phase 2————
One-carbon Therapeutics AB logo
One-carbon Therapeutics ABPrivate
1 asset: 1 Ph 2TH9619Phase 1/2 · Non-Small Cell Lung CancerDec 2026TH9619 · Phase 1/2————
Opna Bio LLC logo
Opna Bio LLCPrivate
1 asset: 1 Ph 1OPN-6602Phase 1 · Multiple MyelomaDec 2027OPN-6602 · Phase 1————
OptiNose, Inc. logo
OptiNose, Inc.Private
1 asset: 1 approvedApproved assets onlyNone on record————
Orano Med Theranostics, SAS logo
Orano Med Theranostics, SASPrivate
1 asset: 1 Ph 1Pb-DOTAM-GRPR1Phase 1 · Non-Small Cell Lung CancerJan 2027Pb-DOTAM-GRPR1 · Phase 1————
Orca Biosystems, Inc. logo
Orca Biosystems, Inc.Private
2 assets: 1 approved, 1 Ph 2OrcaGraft (Orca-Q)Phase 1/2 · Acute Myeloid LeukemiaNov 2027Orca-T · Phase 2————
OriCell Therapeutics Co., Ltd. logo
OriCell Therapeutics Co., Ltd.Private
1 asset: 1 Ph 2OriCAR-017Phase 1/2 · Multiple Myeloma30 Nov 2026OriCAR-017 · Phase 1/2————
OrsoBio logo
OrsoBioPrivate
2 assets: 1 Ph 2, 1 Ph 1TLC-2716Phase 2 · HypertriglyceridemiaNone on record————
O
Osmotica Pharmaceuticals US LLCPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
Oxford Vacmedix UK Ltd. logo
Oxford Vacmedix UK Ltd.Private
1 asset: 1 Ph 1OVM-200Phase 1 · Non-Small Cell Lung CancerNone on record————
Pacylex Pharmaceuticals logo
Pacylex PharmaceuticalsPrivate
1 asset: 1 Ph 1ZelenirstatPhase 1 · Acute Myeloid LeukemiaNone on record————

Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.

Page123456789101112131415